Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population

type 1 diabetes mortality study

Original article published by Diabetes Care. Click here to read the original article.


Historically, mortality in type 1 diabetes has exceeded that in the general population.
We compared mortality in the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study
cohort to that of the current general U.S. population.

Research Design and Methods

The DCCT (1983–1993) compared intensive versus conventional therapy, with
HbA1c levels of ∼7 vs. 9%, respectively, over an average of 6.5 years of treatment.
EDIC is the observational follow-up study of the DCCT (1994 to the present). Vital
status was ascertained for 97.5% of the original DCCT cohort (n = 1,441) after a
mean of 27 years follow-up. Expected mortality during DCCT/EDIC was estimated
using the current age-, sex-, and race-specific risks in the general U.S. population,
and the observed versus expected mortality compared using standardized mortality
ratios (SMRs) and Poisson regression models.


Mortality in the DCCT intensive therapy group was nonsignificantly lower than
that in the general U.S. population (SMR = 0.88 [95% CI 0.67, 1.16]), whereas
mortality in the DCCT conventional therapy group was significantly greater than
that in the general population (SMR = 1.31 [95% CI 1.05, 1.65]). The SMR increased
with increasing mean HbA1c, and above an HbA1c of 9%, the rate of increase in SMR
among females was greater than that among males.


Overall mortality in the combined DCCT/EDIC cohort was similar to that of the
general population but was higher in the DCCT conventional therapy group. Mortality
increased significantly with increasing mean HbA1c, more so among females
than males, especially for HbA1c >9%.

[su_button url=”” target=”blank” style=”flat” background=”#64b243″ size=”6″ center=”yes” radius=”5″ icon=”icon: angle-right”]Continue Reading[/su_button]

Related News

Research Findings May Provide Answers to Diabetes Complication of Peripheral Neuropathy

Learn More +
Genetics in T1D

DRC’s Take on, “The type 1 diabetes gene TYK2 regulates βcell development and its responses to interferon-α”

Learn More +

DRC Is Excited to Share This Breaking T1D News Announced Yesterday by the FDA

Learn More +